Attendee search 

Founded in 1999, BGI is one of the world's leading life science and genomics organizations.

Wuxi Biocity is a biopharmaceutical company mainly focusing on discovery, development, clinical trials and commercialization of "Best-in-Class" and "First-in-Class" original new drug of oncology and autoimmune diseases. Established in December 2017 in Wuxi, Biocity aims to benefit patients around the world as a pioneer pharmaceutical company in China with sustainable innovation ability and therapeutic products. With the noble mission of "Better Medicine for Better Life", our team always adhere to scientific evidence, while consider unfulfilled medical needs ahead of time, to achieve the goal of patient-centered, full-lifecycle disease management. Biocity's programs successfully entered into clinical stages within three years of efficient operation.



We are honored to have domestic and international academicians, well-known scientists, enterprise and policy specialists, clinical experts in particular, on our advisory board to guide Biocity's scientific, clinical, and strategic development. To reach our long-term goal of sustainable competitive advantages, we collaborate with the Wuxi government on multiple aspects to establish the "Biocity Innovation Institute for Translational Medicine". Thus we can further dig into the translational medical research from the discovery of disease mechanisms to the therapeutic applications of certain scientific achievements. Biocity Innovation Institute will strengthen our R&D ability and innovation capacity, therefore accelerate the popularization and enhancement of translational medicine in Wuxi, Jiangsu.



We have been recognized by many investment firms and intend to conduct an IPO in the very near future. With great efforts, we will bring safe and effective local innovative medicine at the best of times, to meet the increasing medical needs globally.

Corporate Venture Capital function for PTT Global Chemical, the biggest polyolefin manufacturer in Southeast Asia.

Located at the High-Tech center, Silicon Valley, ZJ Future was established in 2013 as a bridge between China and the US to offer accelerating services for domestic enterprises with global perspectives. ​



With the vision of accelerating enterprise development and growth, we leverage the complementary advantages of North America, Europe, South America, and the Asia-Pacific regions to connect high-quality projects with industry leaders, promote academic communications and interactions in high-tech fields, aggregate global entrepreneurial and innovative resources, build an effective and efficient global innovation ecosystem, and develop high-level and multi-field cooperation in the fields of economy, trade, investment, science, and technology.

We are a group of angels selecting top companies to invest.

Big Pharma

华润集团一级利润中心，聚焦生命科学领域投资与合作

Approximately 900,000 people annually in the United States suffer from damage to the articular cartilage and subchondral bone, with the knee being the most commonly affected. Articular cartilage lesions have a limited intrinsic ability to heal and often result in osteoarthritis (OA). Progression to OA poses significant economic burden for the United States, totaling over $300 billion annually, and negatively impacting 54.4 million adults (23% of the population). Current strategies for cartilage restoration include bone marrow stimulation (microfracture) and autologous chondrocyte implantation (ACI). These methods have high failure rates (25-50% at 10 years), prolonged rehabilitation times (> 12 months), and show decreasing efficacy in patients older than 40-50 years of age. 

Sparta Biomedical is developing the first-of-its kind osteochondral repair technology (SBM-01) for support the restoration of the cartilage-bone unit. This purpose-built technology is comprised of a novel biomimetic material possesses cartilage-like properties-- tension, compression, tribology, and fatigue.  The patent-pending surface is combined with a uniquely designed base to promote efficient osseous attachment and stable fixation over the long-term. Sparta’s technology will be a significant advancement in the current surgical standard of care. It will result in substantial pain reduction, immediate weight bearing post-operatively, and full range ambulation.

Sparta has assembled a nationally recognized team of scientists, clinicians, orthopedic regulatory experts to develop SBM-01 rapidly and cost effectively. SBM-01's risk profile enables an efficient regulatory path. Furthermore, it is well positioned to obtain Breakthrough Device Designation from the US FDA.